Related Experiment Video
Updated: Aug 7, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy
M S Roberts1, Z Y Wu, G A Siebert
1Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland 4102, Australia. M.Roberts@mailbox.uq.edu.au
Abstract:
Isolated limb infusion (ILI) is an attractive, less complex alternative to isolated limb perfusion (ILP). It has a lower morbidity in treating localized recurrences and in transit metastases of the limb for tumours such as melanoma, Merkel cell tumour and Kaposi's sarcoma, allowing administration of high concentrations of cytotoxic agent to the affected limb under hypoxic conditions. Melphalan is the preferred cytotoxic agent for the treatment of melanoma by ILP or ILI. We report pharmacokinetic data from 12 patients treated by ILI for tumours of the limb in Brisbane. The kinetics of drug distribution in the limb was calculated using a two-compartment vascular model, where both tissue and infusate act as well-stirred compartments. Analysis of melphalan concentrations in the perfusate during ILI showed good agreement between the values measured and the concentrations predicted by the model. Recirculation and wash-out flow rates, tissue concentrations and the permeability surface area product (PS) were calculated. Correlations between the PS value and the drug concentrations in the perfusate and tissue were supported by the results. These data contribute to a better understanding of the distribution of melphalan during ILI in the limb, and offer the opportunity to optimize the drug regimen for patients undergoing ILI.
Insights
Isolated limb infusion (ILI) offers a simpler method for delivering high-dose melphalan chemotherapy to limb tumors. Pharmacokinetic modeling accurately predicted drug distribution, aiding treatment optimization.
Area of Science:
- Oncology
- Pharmacokinetics
- Medical Devices
Background:
- Isolated limb infusion (ILI) is a less invasive alternative to isolated limb perfusion (ILP).
- ILI allows high-dose cytotoxic drug delivery to limb tumors like melanoma, Merkel cell carcinoma, and Kaposi's sarcoma.
- Melphalan is a key chemotherapeutic agent used in ILI for limb malignancies.
Purpose of the Study:
- To report pharmacokinetic data from patients undergoing ILI for limb tumors.
- To analyze melphalan distribution kinetics within the limb during ILI.
- To validate a pharmacokinetic model for ILI procedures.
Main Methods:
- Pharmacokinetic analysis of melphalan in 12 patients treated with ILI.
- Utilized a two-compartment vascular model to describe drug distribution.
- Measured melphalan concentrations in perfusate and calculated key kinetic parameters.
Main Results:
- The two-compartment model accurately predicted melphalan concentrations in the perfusate.
- Calculated recirculation, wash-out rates, tissue concentrations, and permeability-surface area (PS) product.
- Found correlations between PS values and melphalan concentrations in perfusate and tissue.
Conclusions:
- The study provides valuable pharmacokinetic insights into melphalan distribution during ILI.
- The findings support the accuracy of the applied pharmacokinetic model.
- This understanding can help optimize melphalan dosing regimens for ILI in limb tumor treatment.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions